Traders Recap: salesforce.com, inc. (CRM), Alexion Pharmaceuticals, Inc. (ALXN), Colgate-Palmolive Company (CL)

salesforce.com, inc. (CRM) failed to extend gains with the stock declining -1.04% or $-0.85 to close the day at $80.82 on lower than average trading volume of 5.23M shares, compared to its three month average trading volume of 5.77M. The San Francisco California 94105 based company has been outperforming the application software companies by 9.0991% for last three months and its recent gains have pushed the stock slightly up 18.05% YTD, versus the application software industry which is up 10.74% for the same period. The RSI of 68.76 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. It offers enterprise cloud computing applications and platform services, including Sales Cloud that enables companies to store data, monitor leads and progress, forecast opportunities, gain insights through relationship intelligence, and collaborate around sales on desktop and mobile devices. The company also provides Service Cloud that enables companies to deliver personalized customer service and support, as well as connects their service agents with customers on various devices; and Marketing Cloud, which enables companies to plan, personalize, and optimize customer interactions. In addition, it offers Community Cloud that enables companies to engage with groups of people by giving them access to information, applications, and experts; Analytics Cloud, an application, which enables companies to deploy sales, service, marketing, and custom analytics applications using various data source; Internet of Things Cloud that enables customers to process data, as well as build personalized actions and engage with customers in real time; and App Cloud, an application development platform for companies to deliver connected applications for various business needs. Further, the company provides professional services, including consulting, deployment, training, and design and integration services to facilitate the adoption of its cloud solutions, as well as offers various education service offerings ranging from introductory online courses to advanced architecture certifications. It sells and markets services primarily through its direct sales force, as well as through consulting firms, systems integrators, and regional partners. The company has a strategic alliance with Cisco to develop IoT and contact center platforms. salesforce.com, inc. was founded in 1999 and is headquartered in San Francisco, California.

Alexion Pharmaceuticals, Inc. (ALXN) had a active trading with around 5.19M shares changing hands compared to its three month average trading volume of 2.72M. The stock traded between $130.18 and $138.21 before closing at the price of $130.39 with -1.22% change on the day. The New Haven Connecticut 06510 based company is currently trading 19.49% above its 52 week low of $109.12 and -19.51% below its 52 week high of $162. Both the RSI indicator and target price of 53.68 and $167.93 respectively, lead us to believe that it should be put on hold over the coming weeks.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Colgate-Palmolive Company (CL) traded within a range of $68.03 to $69.04 after opening the day at $68.61. The company has seen its stock increase in value by 6.05% so far this year. The stock was up close to 0.57% on active volume in last trading session and closed at $69 per share. After the recent gain, the stock is currently holding -7.43% below its 52 week high of $75.38 and 8.78% above its 12-month low of $63.43. The shares are up by over 4.22% in the last three months, and the RSI indicator value of 66.7 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, and other similar items. It also provides pet nutrition products for everyday nutritional needs, a range of therapeutic products to manage disease conditions, and various products with natural ingredients. The company’s principal global and regional trademarks include Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, elmex, Tom’s of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline, and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet, and Hill’s Ideal Balance. It markets and sells its pet nutrition products for dogs and cats through pet supply retailers and veterinarians. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

 

Three Movers to Watch for: MetLife, Inc. (MET), Mylan N.V. (MYL), Alexion Pharmaceuticals, Inc. (ALXN)

MetLife, Inc. (MET) grew with the stock adding 0.71% or $0.38 to close at $53.88 on light trading volume of 4.93M compared its three months average trading volume of 6M. The New York New York 10166 based company operating under the Life Insurance industry has been trending up for the last 52 weeks, with the shares price now 46.67% up for the period and up by 0.72% so far this year. With price target of $59.86 and a 52.77% rebound from 52-week low, MetLife, Inc. has plenty of upside potential, making it a hold with a view buy.

MetLife, Inc. provides life insurance, annuities, employee benefits, and asset management products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa. The company provides variable, universal, term, and whole life products; individual disability income products; personal lines property and casualty insurance, including private passenger automobile, homeowners, and personal excess liability insurance; and variable and fixed annuities for asset accumulation and distribution needs, as well as mutual funds and other securities products. It also offers group insurance products, such as variable, universal, and term life products; dental, group short- and long-term disability, and accidental death and dismemberment coverages; and voluntary and worksite products consisting of personal lines property and casualty insurance, as well as LTC, prepaid legal plans, and critical illness products. In addition, the company provides annuity and investment products comprising guaranteed interest products and other stable value products, income annuities, and separate account contracts for the investment management of defined benefit and defined contribution plan assets; and structured settlements and products to fund postretirement benefits and company-, bank- or trust-owned life insurance, as well as health insurance, group medical, credit insurance, endowment, retirement, and savings products. It serves individuals and corporations, as well as other institutions and their employees. The company sells its products through sales forces, third-party organizations, independent agents, and property and casualty specialists, as well as through career agency, bancassurance, direct marketing, brokerage, and e-commerce channels. MetLife, Inc. was founded in 1863 and is based in New York, New York.

Mylan N.V. (MYL) gained $0.97 to close the day at a new closing price of $40.75, a 2.44% increase in value from its previous closing price that moved the stock 21.28% above its 52 week low of $33.6. A total of 5.5M shares exchanged hands during the day compared with its three month average trading volume of 5.03M. The stock, which fluctuated between $39.56 and $40.91 during the day, currently situated -19.15% below its 52 week high. The stock is up by 10.94% in the past one month and up by 7.43% over the past three months. With a one year target estimate of $49.84 and RSI of 69.18, the stock still has upside potential, making it a hold for now.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Alexion Pharmaceuticals, Inc. (ALXN) shares were up in last trading by 1.35% to $129.5. It experienced higher than average volume on day. The stock increased in value by almost 1.39% over the past week and fell -5.43% in the past month. It is currently trading 1.49% above its 50 day moving average and 0.36% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -20.06% decrease in value from its one year high of $162. The RSI indicator value of 53.53, lead us to believe that it is a hold for now.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

 

3 Stocks in Focus: Conagra Brands, Inc. (CAG), Analog Devices, Inc. (ADI), Alexion Pharmaceuticals, Inc. (ALXN)

Conagra Brands, Inc. (CAG) climbed 0.28% during last trading as the stock added $0.11 to finish the day at $39.84 with about 1.68M shares changing hands, compared to its three month average trading volume of 3.44M. The $17.29B market cap company, which fluctuated between $39.27 and $39.99 during the day, currently situated 32.4% above its 52 week low of $32.03 and -0.4% away from its one year high of $40. The RSI of 66.79 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Conagra Brands, Inc., together with its subsidiaries, operates as a food company in North America. It operates through five segments: Grocery & Snacks, Refrigerated & Frozen, International, Foodservice, and Commercial. The Grocery & Snacks segment primarily provides branded, shelf-stable food products in various retail channels in the United States. The Refrigerated & Frozen segment offers branded, temperature controlled food products in various retail channels in the United States. The International segment primarily provides branded food products, in various temperature states, in retail and foodservice channels outside of the United States. The Foodservice segment offers branded and customized food products, such as meals, entrees, prepared potatoes, sauces, and various custom-manufactured culinary products packaged for sale to restaurants and other foodservice establishments in the United States. The Commercial segment offers commercially branded and private label food and ingredients primarily to commercial, restaurant, foodservice, food manufacturing, and industrial customers. The company markets its products primarily under the Healthy Choice, Hunt’s, Slim Jim, Reddi-wip, Alexia, Blake’s, Frontera, Bertolli, P.F. Chang’s, and Marie Callender’s brands. The company was formerly known as ConAgra Foods, Inc. and changed its name to Conagra Brands, Inc. in November 2016. Conagra Brands, Inc. was founded in 1919 and is headquartered in Chicago, Illinois.

Analog Devices, Inc. (ADI) gained $0.02 to close the day at a new closing price of $76.53, a 0.03% increase in value from its previous closing price that moved the stock 63.34% above its 52 week low of $49.79. A total of 1.67M shares exchanged hands during the day compared with its three month average trading volume of 2.63M. The stock, which fluctuated between $75.54 and $76.78 during the day, currently situated -1.59% below its 52 week high. The stock is up by 5.38% in the past one month and up by 18.46% over the past three months. With a one year target estimate of $79.58 and RSI of 60.02, the stock still has upside potential, making it a hold for now.

Analog Devices, Inc. designs, manufactures, and markets a portfolio of solutions that leverage analog, mixed-signal, and digital signal processing technology, including integrated circuits (ICs), algorithms, software, and subsystems. It offers data converter products, which translate real-world analog signals into digital data, as well as translates digital data into analog signals; high-performance amplifiers to condition analog signals; and radio frequency ICs to support cellular infrastructure. The company also provides MEMS technology solutions, including accelerometers used to sense acceleration, gyroscopes to sense rotation, and inertial measurement units to sense multiple degrees of freedom. In addition, it offers isolators for various applications, such as universal serial bus isolation in patient monitors; and smart metering and satellite applications. Further, the company provides power management and reference products; and digital signal processing products for high-speed numeric calculations. Its products are used in electronic equipment, including industrial process control systems, medical imaging equipment, factory automation systems, patient monitoring devices, instrumentation and measurement systems, wireless infrastructure equipment, energy management systems, networking equipment, aerospace and defense electronics, optical systems, automobiles, and portable electronic devices. The company serves clients in industrial, automotive, consumer, and communications markets through a direct sales force, third-party distributors, and independent sales representatives in the United States, rest of North/South America, Europe, Japan, China, and rest of Asia, as well as through its Website. It has a collaboration with TriLumina Corp. to provide illuminator modules for automotive flash LiDAR systems. Analog Devices, Inc. was founded in 1965 and is headquartered in Norwood, Massachusetts.

Alexion Pharmaceuticals, Inc. (ALXN) had a light trading with around 1.67M shares changing hands compared to its three month average trading volume of 2.87M. The stock traded between $125.85 and $127.98 before closing at the price of $126.51 with -0.45% change on the day. The New Haven Connecticut 06510 based company is currently trading 15.94% above its 52 week low of $109.12 and -21.91% below its 52 week high of $162. Both the RSI indicator and target price of 46.21 and $167.93 respectively, lead us to believe that it should be put on hold over the coming weeks.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

 

3 Notable Runners: Edwards Lifesciences Corporation (EW), Anthem, Inc. (ANTM), Alexion Pharmaceuticals, Inc. (ALXN)

Edwards Lifesciences Corporation (EW) continued its upward trend with the stock climbing 0.13% or $0.12 to close the day at $90.83 on lower than average trading volume of 1.78M shares, compared to its three month average trading volume of 2.36M. The Irvine California 92614 based company has been outperforming the medical appliances & equipment companies by -0.5818% for last three months and its recent losses have pulled the stock down -3.06% YTD, versus the medical appliances & equipment industry which is up 6.52% for the same period. The RSI of 40.94 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems. Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; pulmonary artery catheters; and continuous venous oximetry catheter for measuring central venous oxygen saturation. Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Anthem, Inc. (ANTM) had a active trading with around 1.77M shares changing hands compared to its three month average trading volume of 1.68M. The stock traded between $156.81 and $159.11 before closing at the price of $158.6 with 0.01% change on the day. The Indianapolis Indiana 46204 based company is currently trading 39.88% above its 52 week low of $114.85 and -1.98% below its 52 week high of $161.8. Both the RSI indicator and target price of 64.99 and $172.71 respectively, lead us to believe that it should be put on hold over the coming weeks.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small employer, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of October 26, 2016, it served 73 million medical members through its affiliated companies. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Alexion Pharmaceuticals, Inc. (ALXN) traded within a range of $125.69 to $128.58 after opening the day at $127.12. The company has seen its stock increase in value by 3.29% so far this year. The stock was down close to -1.06% on light volume in last trading session and closed at $126.37 per share. After the recent fall, the stock is currently holding -21.99% below its 52 week high of $162 and 15.81% above its 12-month low of $109.12. The shares are up by over 5.26% in the last three months, and the RSI indicator value of 43.35 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

 

3 Stocks in Focus: Alexion Pharmaceuticals, Inc. (ALXN), Equity Residential (EQR), Raytheon Company (RTN)

Alexion Pharmaceuticals, Inc. (ALXN) climbed 0.95% during last trading as the stock added $1.21 to finish the day at $128.19 with about 1.68M shares changing hands, compared to its three month average trading volume of 3.2M. The $29.02B market cap company, which fluctuated between $125.31 and $128.3 during the day, currently situated 17.48% above its 52 week low of $109.12 and -20.87% away from its one year high of $162. The RSI of 46.46 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Equity Residential (EQR) gained $0.18 to close the day at a new closing price of $60.56, a 0.3% increase in value from its previous closing price that moved the stock 4.88% above its 52 week low of $58.28. A total of 1.67M shares exchanged hands during the day compared with its three month average trading volume of 2.32M. The stock, which fluctuated between $60.06 and $60.81 during the day, currently situated -13.95% below its 52 week high. The stock is down by -7.05% in the past one month and down by -0.42% over the past three months. With a one year target estimate of $64.83 and RSI of 38.73, the stock still has upside potential, making it a hold for now.

Equity Residential, a real estate investment trust (REIT), engages in the acquisition, development, and management of multifamily properties in the United States. As of December 31, 2007, it owned and invested in 579 properties in 24 states and the District of Columbia consisting of 152,821 units. The company qualifies as a REIT for federal income tax purposes. As a REIT, it would not be subject to federal income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. Equity Residential was founded in 1966 and is headquartered in Chicago, Illinois.

Raytheon Company (RTN) had a light trading with around 1.65M shares changing hands compared to its three month average trading volume of 1.98M. The stock traded between $146.8 and $148.25 before closing at the price of $147.55 with 0.45% change on the day. The Waltham Massachusetts 02451 based company is currently trading 26.33% above its 52 week low of $119.38 and -2.8% below its 52 week high of $152.58. Both the RSI indicator and target price of 54.59 and $167.39 respectively, lead us to believe that it should be put on hold over the coming weeks.

Raytheon Company develops technologically integrated products, services, and solutions worldwide. It operates in five segments: Integrated Defense Systems (IDS); Intelligence, Information, and Services (IIS); Missile Systems (MS); Space and Airborne Systems (SAS); and Forcepoint. The IDS segment provides integrated air and missile defense; land and sea-based radar solutions; command, control, communications, computers, cyber, and intelligence solutions; and naval combat and ship electronic systems. The IIS segment offers a range of technical and professional services, such as intelligence, surveillance and reconnaissance, navigation, DoD space and weather, cybersecurity, analytics, training, logistics, mission support, engineering, and automation and sustainment solutions; and air traffic management systems. The MS segment develops and supports a range of weapon systems, including missiles, smart munitions, close-in weapon systems, projectiles, kinetic kill vehicles, directed energy effectors, and combat sensor solutions. The SAS segment provides electro-optical/infrared sensors, airborne radars for surveillance and fire control applications, lasers, precision guidance systems, signals intelligence systems, processors, electronic warfare systems, communication systems, and space-qualified systems for civil and military applications. The Forcepoint segment provides information technology security products and related services to protect from cyber-threats, advanced malware attacks, information leaks, and legal liability and productivity loss. Raytheon Company serves the U.S. Department of Defense (DoD), the U.S. Intelligence Community, the U.S. Armed Forces, the Federal Aviation Administration, the National Oceanic and Atmospheric Administration, Department of Homeland Security, the National Aeronautics and Space Administration, and other international customers. The company was founded in 1922 and is headquartered in Waltham, Massachusetts.

 

Momentum Stocks in Focus: Alexion Pharmaceuticals, Inc. (ALXN), The Mosaic Company (MOS), The Goldman Sachs Group, Inc. (GS)

Alexion Pharmaceuticals, Inc. (ALXN) failed to extend gains with the stock declining -2.98% or $-3.94 to close the day at $128.38 on light trading volume of 2.82M shares, compared to its three month average trading volume of 3.17M. The New Haven Connecticut 06510 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -12.05%, compared to the industry which has advanced 7.3% over the same period. With RSI of 46.38, the stock should still continue to rise and get closer to its one year target estimate of $167.93, making it a hold for now.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

The Mosaic Company (MOS) retreated with the stock falling -0.73% or $-0.23 to close at $31.45 on light trading volume of 2.81M compared its three months average trading volume of 5.03M. The Plymouth Minnesota 55441 based company operating under the Agricultural Chemicals industry has been trending up for the last 52 weeks, with the shares price now 36.87% up for the period and up by 7.23% so far this year. With price target of $27.26 and a 48.74% rebound from 52-week low, The Mosaic Company has plenty of upside potential, making it a hold with a view buy.

The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients primarily for the agricultural industry worldwide. The company operates through three segments: Phosphates, Potash, and International Distribution. It owns and operates mines, which produce concentrated phosphate crop nutrients, such as diammonium phosphate, monoammonium phosphate, and ammoniated phosphate products; and phosphate-based animal feed ingredients primarily under the Biofos and Nexfos brand names. The company also produces and sells potash for use in the manufacturing of mixed crop nutrients and animal feed ingredients, and for industrial use; and for use in the de-icing and as a water softener regenerant, as well as fluorosilicic acid for water fluoridation. In addition, it provides nitrogen-based crop nutrients and animal feed ingredients, and other ancillary services; and purchases and sells phosphates, potash, and nitrogen products. The company sells its products to wholesale distributors, retail chains, cooperatives, independent retailers, and national accounts. The Mosaic Company was founded in 2004 and is headquartered in Plymouth, Minnesota.

The Goldman Sachs Group, Inc. (GS) failed to extend gains with the stock declining -0.11% or $-0.26 to close the day at $230.41 on lower than average trading volume of 2.77M shares, compared to its three month average trading volume of 4.36M. The New York New York 10282 based company has been outperforming the investment brokerage – national companies by 29.5354% for last three months and its recent gains have offset losses to -3.78% YTD, versus the investment brokerage – national industry which is up 0.65% for the same period. The RSI of 43.07 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

The Goldman Sachs Group, Inc. operates as an investment banking, securities, and investment management company worldwide. It operates through four segments: Investment Banking, Institutional Client Services, Investing & Lending, and Investment Management. The Investment Banking segment provides financial advisory services, such as strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, spin-offs, and risk management; and underwriting services, including public offerings and private placements of various securities and other financial instruments, as well as derivative transactions entered into with public and private sector clients. The Institutional Client Services segment is involved in client execution activities related to making markets in interest rate products, credit products, mortgages, currencies, commodities, and equities; and provides securities services, such as financing, securities lending, and other prime brokerage services, as well as markets in and clears client transactions on primary stock, options, and futures exchanges. The Investing & Lending segment invests in and originates longer-term loans to provide financing to clients; and makes investments in debt securities and loans, public and private equity securities, and real estate entities. The Investment Management segment offers investment management products and services; and wealth advisory services, including portfolio management and financial counseling, and brokerage and other transaction services. The company serves corporations, financial institutions, governments, and individuals. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

 

Stocks in Review: Mylan N.V. (MYL), Digital Realty Trust, Inc. (DLR), Alexion Pharmaceuticals, Inc. (ALXN)

Mylan N.V. (MYL) traded within a range of $36.41 to $38.09 after opening the day at $37.02. The company has seen its stock decrease in value by -0.26% so far this year. The stock was up close to 4.71% on active volume in last trading session and closed at $38.05 per share. After the recent gain, the stock is currently holding -28.49% below its 52 week high of $53.21 and 13.24% above its 12-month low of $33.6. The shares are up by over 2.31% in the last three months, and the RSI indicator value of 56.71 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.’s biosimilar candidates. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hertfordshire, the United Kingdom.

Digital Realty Trust, Inc. (DLR) managed to rebound with the stock climbing 1.14% or $1.21 to close the day at $107.63 on light trading volume of 1.3M shares, compared to its three month average trading volume of 1.5M. The San Francisco California 94111 based company has been outperforming the reit – office group over the past 52 weeks, with the stock gaining 40.33%, compared to the industry which has advanced 31.28% over the same period. With RSI of 72.56, the stock should still continue to rise and get closer to its one year target estimate of $107.73, making it a hold for now.

Digital Realty Trust, Inc., a real estate investment trust (REIT), through its controlling interest in Digital Realty Trust, L.P., engages in the ownership, acquisition, development, redevelopment, and management of technology-related real estate. It focuses on strategically located properties containing applications and operations critical to the day-to-day operations of technology industry tenants and corporate enterprise datacenter users, including the information technology departments of Fortune 1000 companies, and financial services companies. The company’s property portfolio consists of Internet gateway properties, corporate datacenter properties, technology manufacturing properties, and regional or national offices of technology companies. As of December 31, 2008, Digital Realty’s portfolio consisted of 75 properties, including 62 located in North America and 13 located in Europe. Digital Realty Trust has elected to be treated as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its stockholders. The company was founded in 2004 and is headquartered in San Francisco, California with additional offices in Boston, Chicago, Dallas, Los Angeles, New York, Northern Virginia, and Phoenix, as well as in Dublin, London, and Paris.

Alexion Pharmaceuticals, Inc. (ALXN) gained $2.63 to close the day at a new closing price of $130.68, a 2.05% increase in value from its previous closing price that moved the stock 19.76% above its 52 week low of $109.12. A total of 2.05M shares exchanged hands during the day compared with its three month average trading volume of 3.16M. The stock, which fluctuated between $126.1 and $131.07 during the day, currently situated -19.33% below its 52 week high. The stock is up by 5.7% in the past one month and down by -3.62% over the past three months. With a one year target estimate of $167.93 and RSI of 50.41, the stock still has upside potential, making it a hold for now.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

 

Three Movers to Watch for: TransDigm Group Incorporated (TDG), The Allstate Corporation (ALL), Alexion Pharmaceuticals, Inc. (ALXN)

TransDigm Group Incorporated (TDG) retreated with the stock falling -0.41% or $-0.9 to close at $219 on light trading volume of 1.29M compared its three months average trading volume of 857.14K. The Cleveland Ohio 44114 based company operating under the Aerospace/Defense Products & Services industry has been trending up for the last 52 weeks, with the shares price now 9.17% up for the period and down by -12.03% so far this year. With price target of $295 and a 32.44% rebound from 52-week low, TransDigm Group Incorporated has plenty of upside potential, making it a hold with a view buy.

TransDigm Group Incorporated designs, produces, and supplies aircraft components in the United States. The company’s Power & Control segment provides mechanical/electro-mechanical actuators and controls, ignition systems and engine technology, specialized pumps and valves, power conditioning devices, specialized AC/DC electric motors and generators, databus and power controls, hoists, winches and lifting devices, and cargo loading and handling systems. This segment serves engine and power system and subsystem suppliers, airlines, third party maintenance suppliers, military buying agencies, and repair depots. Its Airframe segment offers engineered latching and locking devices, rods and locking devices, engineered connectors and elastomers, cockpit security components and systems, aircraft audio systems, lavatory components, seat belts and safety restraints, engineered interior surfaces and related components, lighting and control technology, military personnel parachutes, and cargo delivery systems. This segment serves airframe manufacturers, cabin system and subsystem suppliers, airlines, third party maintenance suppliers, military buying agencies, and repair depots. The company’s Non-aviation segment provides seat belts and safety restraints for ground transportation applications; mechanical/electro-mechanical actuators and controls for space applications; and refueling systems for heavy equipment. It serves off-road vehicle and subsystem, child restraint system, and satellite and space system suppliers; and manufacturers of heavy equipment. The company also offers aerospace pneumatic and hydraulic components and subsystems for commercial transport, regional, business jet, and military applications; extruded plastic interior parts for use in the commercial aerospace industry; faucets and related products for use on commercial transports and regional jets; and unit load devices. TransDigm Group Incorporated was founded in 1993 and is based in Cleveland, Ohio.

The Allstate Corporation (ALL) dropped $-0.22 to close the day at a new closing price of $75.59, a -0.29% decrease in value from its previous closing price that moved the stock 32.82% above its 52 week low of $58.29. A total of 1.28M shares exchanged hands during the day compared with its three month average trading volume of 2.26M. The stock, which fluctuated between $75.22 and $75.81 during the day, currently situated -0.34% below its 52 week high. The stock is up by 1.45% in the past one month and up by 11.77% over the past three months. With a one year target estimate of $80.13 and RSI of 64.37, the stock still has upside potential, making it a hold for now.

The Allstate Corporation, together with its subsidiaries, engages in property-liability insurance and life insurance business in the United States and Canada. The company’s Allstate Protection segment sells private passenger auto, homeowners, and other property-liability insurance products under the Allstate, Esurance, and Encompass brand names. It also offers specialty auto products including motorcycle, trailer, motor home, and off-road vehicle insurance policies; other personal lines products including renter, condominium, landlord, boat, umbrella, and manufactured home insurance policies; commercial lines products for small business owners; roadside assistance products; service contracts; and other products sold in conjunction with auto lending and vehicle sales transactions. In addition, this segment sells its products through contact centers and Internet. The company’s Allstate Financial segment provides traditional, interest-sensitive, and variable life insurance; and voluntary accident and health insurance products; deferred and immediate fixed annuities; and funding agreements backing medium-term notes; and retirement and investment products, including mutual funds, fixed and variable annuities, disability insurance, and long-term care insurance. This segment markets its products through its agencies and financial specialists, and workplace enrolling independent agents. The Allstate Corporation was founded in 1931 and is headquartered in Northbrook, Illinois.

Alexion Pharmaceuticals, Inc. (ALXN) shares were up in last trading by 0.8% to $129.23. It experienced lighter than average volume on day. The stock decreased in value by almost -2.08% over the past week and grew 2.51% in the past month. It is currently trading 2.8% above its 50 day moving average and -1.06% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -20.23% decrease in value from its one year high of $162. The RSI indicator value of 48.48, lead us to believe that it is a hold for now.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

 

Stocks Trend Analysis: Alexion Pharmaceuticals, Inc. (ALXN), Williams Partners L.P. (WPZ), AMETEK, Inc. (AME)

Alexion Pharmaceuticals, Inc. (ALXN) continued its downward trend with the stock declining -0.32% or $-0.41 to close the day at $129.46 on light trading volume of 2.05M shares, compared to its three month average trading volume of 3.27M. The New Haven Connecticut 06510 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -15.19%, compared to the industry which has advanced 2.66% over the same period. With RSI of 48.8, the stock should still continue to rise and get closer to its one year target estimate of $167.6, making it a hold for now.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Williams Partners L.P. (WPZ) grew with the stock adding 2.76% or $1.1 to close at $40.95 on active trading volume of 2.02M compared its three months average trading volume of 1.52M. The Oklahoma City Oklahoma 73105 based company operating under the Oil & Gas Pipelines industry has been trending up for the last 52 weeks, with the shares price now 108.37% up for the period and up by 7.68% so far this year. With price target of $55 and a 248.63% rebound from 52-week low, Williams Partners L.P. has plenty of upside potential, making it a hold with a view buy.

Williams Partners L.P. operates as an energy infrastructure company. It operates through Central, Northeast G&P, Atlantic-Gulf, West, and NGL & Petchem Services segments. The Central segment provides gathering, treating, and compression services to producers in the Barnett shale region of north-central Texas, the Eagle Ford shale region of south Texas, the Haynesville shale region of northwest Louisiana, and the Mid-Continent region. The Northeast G&P segment engages in the natural gas gathering and processing, and NGL fractionation businesses in the Marcellus and Utica shale regions in Pennsylvania, West Virginia, New York, and Ohio. The Atlantic-Gulf segment engages in the interstate natural gas pipeline; and natural gas gathering and processing, and crude oil production handling and transportation activities in the Gulf Coast region. The West segment engages in the natural gas gathering, processing, and treating operations in New Mexico, Colorado, and Wyoming, as well as operates the interstate natural gas pipeline and the Northwest Pipeline. The NGL & Petchem Services segment engages in the operation of an olefins production facility in Geismar, Louisiana; a refinery grade propylene splitter, and various petrochemical and feedstock pipelines in the Gulf Coast region; an oil sands offgas processing plant near Fort McMurray, Alberta; an (natural gas liquids) NGL/olefin fractionation facility; and storage facilities and an NGL fractionator near Conway, Kansas, as well as NGL and natural gas marketing business. WPZ GP LLC serves as the general partner of the company. The company was founded in 2005 and is based in Tulsa, Oklahoma. Williams Partners L.P. operates as a subsidiary of Williams Companies, Inc.

AMETEK, Inc. (AME) continued its upward trend with the stock climbing 2.38% or $1.22 to close the day at $52.4 on lower than average trading volume of 2.02M shares, compared to its three month average trading volume of 2.38M. The Berwyn Pennsylvania 19312 based company has been outperforming the diversified machinery companies by 16.2603% for last three months and its recent gains have pushed the stock slightly up 7.82% YTD, versus the diversified machinery industry which is up 1.59% for the same period. The RSI of 70 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices worldwide. The company’s Electronic Instruments Group segment provides advanced instruments for the process, aerospace, power, and industrial markets; process and analytical instruments for the oil, gas, petrochemical, pharmaceutical, semiconductor, and factory automation markets; instruments for the laboratory equipment, ultra precision manufacturing, medical, and test and measurement markets; and vision systems for surface inspection. This segment also offers aircraft and engine sensors, monitoring systems, power instruments, data acquisition units, and fuel and fluid measurement systems for the aerospace industry; power quality monitoring and metering devices, industrial battery chargers, uninterruptible power supplies, programmable power and electrical test equipment, and gas turbine sensors; and dashboard instruments for heavy trucks and other vehicles, as well as timing controls and cooking computers for the food service industry. Its Electromechanical Group segment provides electrical interconnects, specialty metals, thermal management systems, and floor care and specialty motors; precision motion control products for data storage, medical devices, business equipment, factory automation, and other applications; engineered electrical connectors and packaging products to protect sensitive electronic devices; and metal tubing products. This segment also offers high-purity metals, metal strips, shaped wires, and advanced composites for various industrial applications; and motors used in commercial appliances, fitness equipment, food and beverage machines, hydraulic pumps, industrial blowers, and vacuum cleaners, as well as operates a network of aviation maintenance, repair, and overhaul facilities. The company sells its products through direct sales force, sales representatives, and distributors. AMETEK, Inc. was founded in 1930 and is headquartered in Berwyn, Pennsylvania.

 

Equities Trend Analysis: Fortinet, Inc. (FTNT), Alexion Pharmaceuticals, Inc. (ALXN), Danaher Corporation (DHR)

Fortinet, Inc. (FTNT) grew with the stock adding 0.47% or $0.15 to close at $31.85 on light trading volume of 2.12M compared its three months average trading volume of 2.5M. The Sunnyvale California 94086 based company operating under the Application Software industry has been trending up for the last 52 weeks, with the shares price now 20.37% up for the period and up by 5.74% so far this year. With price target of $35.48 and a 37.52% rebound from 52-week low, Fortinet, Inc. has plenty of upside potential, making it a hold with a view buy.

Fortinet, Inc. provides cyber security solutions for enterprises, service providers, and government organizations worldwide. The company offers FortiGate physical and virtual appliances products that provide various security and networking functions, including firewall, intrusion prevention, anti-malware, virtual private network, application control, Web filtering, anti-spam, and wide area network acceleration; FortiManager product family to provide a central management solution for FortiGate products comprising software updates, configuration, policy settings, and security updates; and the FortiAnalyzer product family, which provides a single point of network log data collection. It also offers FortiAP secure wireless access points; FortiWeb, a Web application firewall; FortiMail email security; FortiDB database security appliances; FortiClient, an endpoint security software; and FortiSwitch secure switch connectivity products. In addition, the company provides FortiSandbox advanced threat protection solutions; and FortiDDos and FortiDB database security appliances. Further, it offers security subscription, technical support, training, and professional services. The company was founded in 2000 and is headquartered in Sunnyvale, California.

Alexion Pharmaceuticals, Inc. (ALXN) had a light trading with around 2.12M shares changing hands compared to its three month average trading volume of 3.21M. The stock traded at the price of $135.87 with 0.42% change on the day. The New Haven Connecticut 06510 based company is currently trading 24.51% above its 52 week low of $109.12 and -17.01% below its 52 week high of $162. Both the RSI indicator and target price of  and $169.45 respectively, lead us to believe that it could rise over the coming weeks.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Danaher Corporation (DHR) saw its value increase by 0.35% as the stock gained $0.28 to finish the day at a closing price of $81.19. The stock was lighter in trading and has fluctuated between $61.6-$82.64 per share for the past year. The shares, which traded within a range of $81 to $81.6 during the day, are up by 7.2% in the past three months and up by 0.7% over the past six months. It is currently trading 2.15% above its 20 day moving average and 2.89% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $89.72 a share over the next twelve months. The current relative strength index (RSI) reading is 62.11.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. Its Test & Measurement segment provides instruments products; services and products that help to convert concepts into finished products; professional tools; and wheel service equipment. The company’s Environmental segment provides instrumentation and disinfection systems; and solutions and services focused on fuel dispensing, remote fuel management, point-of-sale and payment system, environmental compliance, vehicle tracking, and fleet management. Its Life Sciences & Diagnostics segment offers chemistry systems, immunoassay systems, hematology and flow cytometry products, microbiology systems, and systems and workflow automations solutions. This segment also provides professional microscopes; mass spectrometers; bioanalytical measurement systems; workflow instruments and consumables; and filtration products, which are used to remove solid, liquid, and gaseous contaminants. The company’s Dental segment offers consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. The company’s Industrial Technologies segment provides equipment, consumables, and software for various printing, marking, coding, packaging, design, and color management applications; and a range of electromechanical and electronic motion control products. This segment also offers devices that sense, monitor and control operational or manufacturing variables; instruments, controls, and monitoring systems used in electric utilities and industrial facilities; engineered energetic materials components; and supplemental braking systems for commercial vehicles. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.